Form 4: Femasys Grants 100,000 Stock Options to Chief Commercial Officer Nicholas Kelley Stinson

Femasys Inc. has granted 100,000 stock options to its Chief Commercial Officer, Nicholas Kelley Stinson, with an exercise price of $0.90 per share.

Summary

• Nicholas Kelley Stinson, Chief Commercial Officer of Femasys Inc. (FEMY), was granted 100,000 stock options.
• The transaction date for this grant was June 23, 2025.
• Each stock option has an exercise price of $0.90.
• The options vest equally in installments over four years, commencing on June 23, 2025.
• Vesting is contingent upon Mr. Stinson's continued employment with Femasys Inc. or its subsidiaries on each vesting date.
• The expiration date for these stock options is June 23, 2035.
• Following this transaction, Mr. Stinson beneficially owns 100,000 derivative securities directly.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the grant of stock options aligns executive interests with shareholder value, which is generally viewed favorably, despite the potential for future dilution.

Positives

• The grant of stock options aligns the interests of Chief Commercial Officer Nicholas Kelley Stinson with those of shareholders, incentivizing long-term performance and growth.
• The options provide a performance incentive for a key executive, potentially contributing to the company's future success.

Negatives

• The exercise of these options in the future could lead to a degree of share dilution for existing shareholders.

Future Outlook

This Form 4 filing does not provide a general future outlook for the company, but the stock option grant indicates a long-term incentive for the Chief Commercial Officer.

Industry Context

This filing is a standard disclosure of an executive compensation event within the biotechnology or medical device industry, reflecting common practices for incentivizing key personnel through equity grants.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also benefit from increased alignment of executive incentives with company performance.
• Employees (Nicholas Kelley Stinson): Direct impact through the grant of long-term equity compensation, contingent on continued employment.

Next Steps

• The stock options will vest in equal installments over the next four years, starting June 23, 2025.
• Nicholas Kelley Stinson may exercise the vested options at any time before their expiration date of June 23, 2035, provided he remains employed by the Issuer or a subsidiary.

Key Dates

Keywords

FEMY, FEMASYS INC, Stock Option, Executive Compensation, Insider Transaction, Form 4, Nicholas Kelley Stinson, Derivative Securities